title: Effect of prior treatment with resveratrol on density and structure of rat long bones under tail-suspension.
abstract: Physical inactivity during space flight or prolonged bed rest causes rapid and marked loss of bone mass in humans. Resveratrol, a red wine polyphenol that is currently under study for its therapeutic antioxidant properties, has been shown to significantly modulate biomarkers of bone metabolism, i.e., to promote osteoblast differentiation and to prevent bone loss induced by estrogen deficiency. However, there is no direct evidence supporting its inhibitory effect toward bone loss during physical inactivity. In the present study, effects of resveratrol on bone mineral density (BMD), bone mineral content, and bone structure were examined in the femora and tibiae of tail-suspended and unsuspended rats using X-ray micro-computed tomography (micro-CT). Rats were treated with 400 mg/kg/day of resveratrol for 45 days and half of them were suspended during the last 2 weeks of treatment. Suspension caused a decrease in tibial and femoral BMD and deterioration of trabecular and cortical bone. Bone deterioration during suspension was paralleled by increased bone marrow area, which could be caused by an increase in stromal cells with osteoclastogenic potential or in adipocytes. Resveratrol had a preventive effect against bone loss induced by hindlimb immobilization. In particular, trabecular bone in the proximal tibial metaphysis was totally preserved in rats treated with resveratrol before tail-suspension.
authors.affiliation: Institut Pluridisciplinaire Hubert Curien, CNRS UMR 7178, Université de Strasbourg, 23 rue du Loess, Strasbourg Cedex 2, France. caroline.habold@c-strasbourg.fr
authors.forename: Caroline
authors.initials: C
authors.lastname: Habold
authors.forename: Iman
authors.initials: I
authors.lastname: Momken
authors.forename: Ali
authors.initials: A
authors.lastname: Ouadi
authors.forename: Virgile
authors.initials: V
authors.lastname: Bekaert
authors.forename: David
authors.initials: D
authors.lastname: Brasse
mesh_terms: D000818:Animals; D015519:Bone Density / Q000187:drug effects; D005269:Femur / Q000187:drug effects / Q000378:metabolism; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology*; D013977:Tibia / Q000187:drug effects / Q000378:metabolism; D055114:X-Ray Microtomography
chemical_list: D013267:Stilbenes; D000077185:Resveratrol
references.citation: Lancet. 2000 May 6;355(9215):1607-11
references.pmid: 10821365
references.citation: J Cell Sci. 1987 Jun;87 ( Pt 5):731-8
references.pmid: 3499442
references.citation: Bone. 1995 Oct;17(4 Suppl):353S-364S
references.pmid: 8579938
references.citation: J Bone Miner Res. 2004 Jun;19(6):1006-12
references.pmid: 15125798
references.citation: Phys Med Biol. 2009 Apr 7;54(7):2147-61
references.pmid: 19287088
references.citation: Cell Metab. 2008 Aug;8(2):157-68
references.pmid: 18599363
references.citation: Bone. 1998 May;22(5 Suppl):139S-143S
references.pmid: 9600771
references.citation: Am J Physiol. 1999 Jul;277(1 Pt 2):R1-10
references.pmid: 10409251
references.citation: Cell Tissue Kinet. 1987 May;20(3):263-72
references.pmid: 3690622
references.citation: J Med Food. 2005 Spring;8(1):14-9
references.pmid: 15857203
references.citation: Bone. 2002 Jul;31(1):149-57
references.pmid: 12110428
references.citation: Bone. 2000 Aug;27(2):233-9
references.pmid: 10913916
references.citation: Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):14138-43
references.pmid: 9391166
references.citation: FASEB J. 2003 Nov;17(14):1975-85
references.pmid: 14597667
references.citation: Int J Oncol. 2003 Jul;23(1):17-28
references.pmid: 12792772
references.citation: J Bone Miner Res. 2002 Sep;17(9):1639-45
references.pmid: 12211434
references.citation: J Appl Physiol (1985). 1999 Jun;86(6):1841-6
references.pmid: 10368347
references.citation: Endocrinology. 2007 Jul;148(7):3419-25
references.pmid: 17431002
references.citation: Proc Natl Acad Sci U S A. 1985 Dec;82(23):8213-7
references.pmid: 3865222
references.citation: J Bone Miner Metab. 2002;20(4):216-22
references.pmid: 12115067
references.citation: Phys Med Biol. 2005 Dec 21;50(24):5799-811
references.pmid: 16333156
references.citation: J Comput Assist Tomogr. 1980 Aug;4(4):493-500
references.pmid: 7391292
references.citation: J Pharmacol Exp Ther. 1999 Oct;291(1):321-8
references.pmid: 10490920
references.citation: Aviat Space Environ Med. 1987 Jan;58(1):63-8
references.pmid: 3814035
references.citation: J Clin Invest. 1987 Nov;80(5):1261-9
references.pmid: 3500182
references.citation: Endocrinology. 1999 Jan;140(1):50-4
references.pmid: 9886806
references.citation: Planta Med. 2008 Jun;74(8):794-801
references.pmid: 18537073
references.citation: J Bone Miner Res. 2004 Nov;19(11):1771-8
references.pmid: 15476576
references.citation: J Bone Miner Res. 2002 Apr;17(4):668-77
references.pmid: 11918224
references.citation: J Pediatr Endocrinol Metab. 1998;11(3):421-5
references.pmid: 11517958
references.citation: J Bone Miner Res. 2000 Nov;15(11):2169-77
references.pmid: 11092397
references.citation: J Agric Food Chem. 1999 Aug;47(8):3223-7
references.pmid: 10552635
references.citation: Science. 1978 Sep 22;201(4361):1138-41
references.pmid: 150643
references.citation: Bone. 1998 Jan;22(1):1-6
references.pmid: 9437507
references.citation: Clin Rheumatol. 1989 Jun;8 Suppl 2:95-103
references.pmid: 2667875
references.citation: Cancer Res. 2005 Nov 1;65(21):9943-52
references.pmid: 16267019
references.citation: Am J Physiol. 1993 May;264(5 Pt 1):E790-9
references.pmid: 8498500
references.citation: FASEB J. 1995 Mar;9(5):441-5
references.pmid: 7896017
references.citation: J Bone Miner Res. 1995 Mar;10(3):415-23
references.pmid: 7785463
references.citation: J Bone Miner Res. 2002 Apr;17(4):661-7
references.pmid: 11918223